Ginkgo Bioworks Awarded $40MM NIH RADx-ATP Contract to Expand High Throughput SARS-CoV-2 Testing; Funding will enable expansion of automated Bioworks facility for large scale suppression testing using next generation sequencing

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    PR Newswire (USA), July 31, 2020, 2pp
  • Additional Information
    • Abstract:
      BOSTON, July 31, 2020 /PRNewswire/ -- Today, Ginkgo Bioworks announced it has been awarded a contract from the NIH Rapid Acceleration of Diagnostics Advanced Technology Platforms (RADx-ATP) program to scale its automated technology for SARS-CoV-2 testing using next-generation sequencing (NGS). The contract, which is for a maximum of approximately $40 million, will go toward expanding the operational capacity for large-scale SARS-CoV-2 testing in Ginkgo's automated "Bioworks" facilities...